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OBJECTIVES The aim of this study was to determine whether sulfonylureas attenuate ST-segment
elevation in diabetics during acute myocardial infarction (AMI).
BACKGROUND Sulfonylureas block adenosine triphosphate-sensitive potassium channels found in the
pancreas and heart. Animal studies have demonstrated that opening of these cardiac channels
results in ST-segment elevation during AMI, and pretreatment with sulfonylureas blunts
these ST-segment changes.
METHODS We performed a retrospective study of diabetic patients hospitalized with AMI over a
four-year period in Framingham, Massachusetts. Electrocardiograms obtained on arrival were
analyzed for standard ST-segment criteria for thrombolytic therapy (1 mm in two or more
contiguous leads). Results were compared between the study group (40 patients taking
sulfonylureas) and control group (48 patients taking alternative hypoglycemic agent).
RESULTS Demographics were similar for both groups apart from a female preponderance in the study
group. A significantly higher percentage of patients in the study group did not meet
ST-segment criteria for thrombolytic therapy as compared with the control group (53% vs.
29%, p  0.02). This difference was most prominent in patients with peak creatinine
phosphokinase levels between 500 and 1,000 mg/dl (86% vs. 22%, p 0.04). The magnitude
of ST-segment elevation and the frequency of thrombolytic therapy were significantly lower
in the sulfonylurea group than in the control group (1.1  1.0 mm vs. 2.1  2.7 mm, p 
0.02 and 20% vs. 40%, p  0.04, respectively).
CONCLUSIONS Sulfonylurea therapy appears to attenuate the magnitude of ST-segment elevation during an
AMI, resulting in failure to meet criteria for thrombolytic therapy and as a consequence
leading to inappropriate withholding therapy in this subset of diabetic patients. (J Am Coll
Cardiol 2003;42:1017–21) © 2003 by the American College of Cardiology Foundation
Diabetes mellitus is a major risk factor for the development
of coronary artery disease, conferring more than a three-fold
increased risk for acute coronary syndromes and congestive
heart failure (1). Sulfonylureas are commonly used as
first-line drugs for glycemic control.
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These agents stimulate insulin release from pancreatic
beta cells via blocking of adenosine triphosphate-sensitive
potassium (KATP) channels (2–4). These channels are also
found in the heart and smooth muscle. The channels are
normally closed during steady state in heart muscle, inhib-
ited by adenosine triphosphate (ATP). During ischemia,
when ATP falls and adenosine diphosphate (ADP) in-
creases, the channels open (2–8). Animal studies have
shown that opening of these channels results in ST-segment
elevation on the electrocardiogram (ECG) during an acute
ischemic event (5–7).
Experimental studies have demonstrated that ST-
segment elevation during acute myocardial injury can be
blunted by pretreating animals with the sulfonylurea, glyburide
(5–7,9); however, there are no human studies that address this
issue. The purpose of this study was to discern whether
sulfonylurea drugs affect ST-segment elevation in diabetics
with an acute myocardial infarction (AMI), because the under-
use of thrombolytics in diabetics has important implications.
METHODS
We retrospectively reviewed the charts of all diabetic pa-
tients admitted to the coronary care unit of our community
hospital, MetroWest Medical Center (Framingham, Mas-
sachusetts), with the diagnosis of AMI from October 1996
through August 2000. Patients with no more than 24 h of
symptoms and a positive creatinine phosphokinase (CPK)
elevation were selected for the study. All diabetic patients were
included for study purposes regardless of the hypoglycemic
regimen, from diet control only and no medical therapy, to any
kind of sulfonylureas, biguanides, glitazones, and/or insulin.
Patients presenting with a left or right bundle-branch
block, fully paced rhythm, left ventricular hypertrophy with
strain pattern by ECG, or digoxin therapy were excluded
from analysis.
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We reviewed demographic data as well as the ECG on
presentation to the emergency department. The population
was divided into two groups: those taking sulfonylurea drugs
(study group) and those treated with non-sulfonylurea
hypoglycemic agents (control group). Each group was fur-
ther categorized into three subgroups based on peak CPK
level (as a surrogate for size of myocardial infarction): group
1  peak CPK 500 mg/dl; group 2  peak CPK 500 to
1,000 mg/dl; and group 3  peak CPK 1,000 mg/dl.
The first ECG obtained in the emergency room was
chosen for ST-segment analysis. A single physician was
assigned to blindly analyze all ECGs for ST-segment
changes. A baseline was traced horizontally in all leads, and
ST-segment elevation and/or depression was measured at
20 to 40 ms after the J point in all affected leads. An average
ST-segment elevation and/or depression was obtained in all
affected contiguous leads. Each patient had an average
ST-segment elevation and depression that was used for
statistical analysis. The ECGs were classified as either
meeting or not (non-diagnostic ST-segment elevation) the
standard ST-segment elevation criteria for thrombolytic
therapy for AMI (1 mm ST-segment elevation in two or
more contiguous leads). The prevalence of non-diagnostic
ST-segment elevation was analyzed for each group (study
group vs. control group).
Statistical analysis. Data were analyzed with SAS software
(SAS Institute, Cary, North Carolina). Chi-square was used
to compare all demographic data, ST-segment characteris-
tics, and non-diagnostic ECG between the control and the
sulfonylurea groups. The Fisher exact test was used for
subgroup analysis. Differences were considered statistically
significant at p  0.05.
RESULTS
A total of 147 diabetics were admitted to MetroWest
Medical Center with AMI from October 1996 to August
2000. Only 88 diabetic patients met the criteria for inclusion
in the study, 40 patients taking sulfonylurea drugs (study
group) and 48 patients taking other hypoglycemic agents
(control group). The remaining 59 patients were excluded
(18 patients on digoxin, 8 and 17 patients with right and left
bundle-branch block, respectively, 3 patients with a fully
paced rhythm, 2 patients with left ventricular hypertrophy-
strain pattern, and 11 patients with more than 24 h of
symptoms). Demographic data and baseline characteristics
were similar for both groups (Table 1) except for gender,
with a clear preponderance of females in the study group.
The sulfonylurea group had 25 patients (63%) with peak
CPK 500 mg/dl, 7 patients (17%) with peak CPK 500 to
1,000 mg/dl, and 8 patients (20%) with peak CPK 1,000
mg/dl. The control group had 19 patients (40%) with peak
CPK 500 mg/dl, 9 patients (18%) with peak CPK 500 to
1,000 mg/dl, and 20 patients (41%) with peak CPK1,000
mg/dl.
The prevalence of ECGs not meeting ST-segment ele-
vation criteria for thrombolytics (non-diagnostic ST-
segment elevation) in both groups is depicted in Figure 1.
Overall, we found a significantly greater number of non-
diagnostic ST-segment elevation in the sulfonylurea group
as compared with the control group (53% vs. 29%, p 
0.02). This difference was most pronounced for patients
with a peak CPK level between 500 and 1,000 mg/dl (86%
vs. 22%, p  0.04). There was no significant difference in
the frequency of non-diagnostic ST-segment elevation in
patients with a peak CPK 500 mg/dl (59% vs. 64%, p 
NS) or 1,000 mg/dl (25% vs. 15%, p  NS). The
magnitude of ST-segment elevation in the sulfonylurea
group was significantly less than in the control group (mean
1.1  1.0 mm vs. 2.1  2.7 mm, p  0.02), whereas there
Abbreviations and Acronyms
ADP  adenosine diphosphate
AMI  acute myocardial infarction
ATP  adenosine triphosphate
CPK  creatinine phosphokinase
ECG  electrocardiogram
K  potassium
KATP  adenosine triphosphate-sensitive potassium
Table 1. Demographic Data and Baseline Characteristics of 88
Diabetic Patients With Diagnosis of Acute MI
Data
Sulfonylurea
(n  40)
Control
(n  48)
Age (SD), yrs 70.4  13 66  14
Females* 21 (52%) 12 (25%)
Smoking 11 (28%) 11 (23%)
Hyperlipidemia 19 (48%) 24 (50%)
Hypertension 29 (72%) 33 (68%)
Angina 13 (33%) 14 (29%)
Previous MI 13 (33%) 11 (23%)
Coronary bypass 4 (10%) 6 (13%)
LAFB 6 (15%) 6 (12.5%)
Atrial fibrillation 3 (7.5%) 3 (6.25%)
Ejection fraction 42% 42%
ASA 15 (37.5%) 25 (52%)
Beta-blockers 13 (33%) 17 (35%)
Ca2 channel blocker 15 (38%) 19 (40%)
ACE inhibitors 13 (33%) 21 (43%)
Nitrates 6 (15%) 3 (27%)
Diuretics 8 (20%) 15 (31%)
Peak CPK 1,000 (mg/dl) 2,233.6 2,232.2
Peak CPK 500–1,000 (mg/dl) 698.6 682.0
Peak CPK 500 (mg/dl) 333.1 310.0
Glycosylated hemoglobin (%) 8.7  1.7 9.1  2.0
Admitting blood glucose (mg/dl) 260  83 268  129
Hypoglycemic regimen
No therapy 0 15 (31%)
Diet–control only 0 10 (20%)
Insulin (NPH, ultralente, 70/30) 0 23 (48%)
Biguanide (metformin) 6 (15%) 2 (4%)
Glitazones 0 1 (2%)
*p  0.004.
ACE  angiotensin-converting enzyme; ASA  acetylsalicylic acid; CPK 
creatinine phosphokinase; LAFB  left anterior fascicular block; MI  myocardial
infarction; NPH  neutral protamine Hagedorn (isophane insulin suspension).
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was no difference in average ST-segment depression (0.8 
0.7 mm vs. 1.0  1.0 mm, p  NS). Thrombolytic therapy
was administered less frequently in the sulfonylurea group as
compared with the control group (20% vs. 40%, p  0.04),
with no difference in the duration of symptoms or contraindi-
cations to thrombolytic therapy between groups (Table 2).
Analysis of the male population (55 patients) alone
demonstrated significantly less magnitude of ST-segment
elevation in the sulfonylurea group when compared with the
control group (mean 1.2  0.9 mm vs. 2.3  2.9 mm, p 
0.04) (Table 2). However, the trend of non-diagnostic
ST-segment elevation in the sulfonylurea and control
groups (47% vs. 25%, p  0.09) did not reach statistical
significance (Fig. 2).
DISCUSSION
This is the first pilot study suggesting that sulfonylurea
drugs may attenuate ST-segment elevation during an AMI.
These medications are known to block the cardiac KATP
channels. Cardiac KATP channels are located in the cyto-
plasmic and mitochondrial membrane (2–8,10). Glipizide
and glyburide have greater affinity for the cytoplasmic
cardiac KATP channels than glimepiride and the first-
generation sulfonylureas (3,11).
The function of the cardiac cytoplasmic KATP channel
under physiologic conditions is unclear; however, its func-
tion during ischemia is partially known. These KATP chan-
nels are normally closed in non-hypoxic heart tissue. It is
only during ischemia, when ATP falls and ADP rises (ATP
not being regenerated from ADP through oxidative phos-
phorylation), that these channels open. Activation of KATP
channels mediates an efflux and extracellular accumulation
of potassium (K) with resultant hyperpolarization of the
cell and shortening of the action potential. This shortening
of the action potential is thought to predispose to lethal
arrhythmias by promoting re-entry during ischemia (2–8).
An experimental study demonstrated that the opening of
KATP channels plays an important role in the development
of ECG ST-segment elevation during myocardial injury (6).
This study showed that ST-segment elevation during acute
myocardial injury in animals could be blunted by glyburide
(KATP channel blocker), but potentiated by pinacidil (KATP
channel opener) in non-ischemic tissue. By reducing the
ischemia-related accumulation of K in the extracellular
space, treatment with sulfonylureas may lead to less hyper-
polarization of the resting membrane potential within the
ischemic area and thus less ST-segment elevation on the
surface ECG (5–7).
We found that diabetic patients with AMI who were
Figure 1. Non-diagnostic ST-segment elevation during acute myocardial infarction, subdivided by infarct size (total of 88 patients). White bars  control;
black bars  sulfonylureas. CPK  creatinine phosphokinase.
Table 2. Results: Electrocardiographic ST-Segment Changes
and Thrombolytic Therapy in the Overall Study Population and
in Males Alone
Overall Study Population
Data
Sulfonylurea
(n  40)
Control
(n  48)
Hours of symptoms 7  6.2 8.5  7.2
Thrombolytics contraindicated 3 (8%) 3 (6%)
Thrombolysis* 8 (20%) 19 (40%)
Mean ST-segment elevation (SD), mm† 1.1 (1.0) 2.1 (2.7)
Mean ST-segment depression (SD), mm 0.8 (0.7) 1.0 (1.0)
Males
Data
Sulfonylurea
(n  19)
Control
(n  36)
Thrombolysis 5 (26%) 17 (47%)
Mean ST-segment elevation (mm)* 1.2 2.3
Mean ST-segment depression (mm) 0.8 0.9
*p  0.04; †p  0.02.
SD  standard deviation.
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taking sulfonylureas were less likely to meet the standard
ECG criteria for administration of thrombolytic therapy
(Fig. 1, Table 2). Those patients on sulfonylurea drugs had
a reduced magnitude of ST-segment elevation during AMI
as compared with diabetics not on sulfonylureas (Table 2).
For CPK levels between 500 and 1,000 mg/dl, the differ-
ence was statistically significant. In patients with CPK
1,000 mg/dl, there was a trend toward a greater number of
non-diagnostic ST-segment elevation in the sulfonylurea
group, though this did not reach statistical significance. It is
possible that the greater the extent of myocardial injury, the
less the attenuation of the ST-segment elevation caused by
sulfonylurea drugs, owing to the overwhelming number of
cardiac KATP channels that open.
There was no difference in the frequency of non-
diagnostic ST-segment elevation in patients with peak CPK
levels 500 mg/dl. The control group with CPK levels
500 mg/dl was the only subgroup to have a small trend
towards more non-diagnostic ST-segment elevation, partic-
ularly in the female population. However, these smaller
CPK levels are more characteristic of non–Q-wave AMI,
which generally presents with no ST-segment changes
because the small area of tissue involved is not reflected on
the epicardial surface. We believe this could explain the
limited impact of sulfonylureas in the subgroup with peak
CPK levels 500 mg/dl.
Interestingly, the control group had a greater percentage
of AMI with CPK 500 mg/dl as compared with the
sulfonylurea group (59% vs. 37%, p  0.05). The nature of
this finding is unclear, though we could only speculate that
this could have been the result of a higher thrombolytic use
in the control group with a subsequent rapid washout of
cardiac enzymes. Sulfonylureas are not known to have a
cardioprotective effect in AMI size. In fact, these medica-
tions have been implicated in the interference of ischemic
preconditioning during acute ischemic events, resulting in a
larger size of AMI (12–17).
Because of the difference in gender composition of the
sulfonylurea and control groups, we cannot exclude the
possibility that the results were due to the female prepon-
derance in the study group. The significant difference in
mean ST-segment elevation between groups in the male
population (Table 2) suggests that the attenuation of the
ST-segment elevation could be truly due to the sulfonylurea
drug rather than the gender differences between groups.
Unfortunately, the rest of the male subgroup analysis did
not provide us with any concrete reassurance that these
findings were not attributable to gender difference. We must
be cautious in drawing any conclusions from the male
subgroup analysis because the number of patients was small.
Mortality was not an end point in this study. In the
1970s, an increase in cardiovascular mortality was attributed
to tolbutamide (18). We found that patients taking sulfo-
nylureas received less thrombolytic therapy when compared
with diabetics treated with other hypoglycemic agents
(Table 2). Recently, a non-randomized trial showed an
increased mortality in diabetics treated with sulfonylureas
after direct angioplasty for AMI (19). However, the United
Kingdom Prospective Diabetes Study (UKPDS) trial (20)
and a study by Brady et al. (21) noted that the second-
generation sulfonylureas do not increase mortality during
acute coronary events. Furthermore, sulfonylureas have also
been demonstrated to have antiarrhythmic properties, de-
creasing lethal arrhythmias during acute coronary events by
attenuating action potential shortening (re-entry mecha-
nism) (9,22–25). Thus, we believe that these medications
may not affect overall cardiovascular mortality when both
effects are taken into consideration.
Figure 2. Non-diagnostic ST-segment elevation during acute myocardial infarction. Males (55 patients) compared with overall study population (88
patients) subdivided by infarct size. White bars  control; black bars  sulfonylureas. CPK  creatinine phosphokinase.
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Our study is subject to the inherent limitations of a
retrospective study. The sample size is too small to detect
statistically significant differences in subgroup analysis. We
cannot exclude the possibility that the attenuation of ST-
segment elevation (non-diagnostic ST-segment elevation)
in the sulfonylurea group was related to the preponderance
of women. However, the significant difference in mean
ST-segment elevation in the male population (Table 2)
leads us to believe that the attenuation of the ST-segment
elevation is a true drug-related effect. Another limitation to
consider is the possibility of different sizes of myocardial
infarctions between sulfonylurea and control groups, even with
exactly the same CPK level, due to a rapid washout of enzymes
in the patients receiving thrombolytic therapy. Unfortunately,
there is no gold standard to assess the true size of an AMI.
Few reports consider initial ECG to be non-diagnostic in
45% of all patients shown to have an AMI (26). We present
a pilot study, because sample size estimate was particularly
difficult to calculate in diabetics owing to the lack of data of
non-diagnostic ECG in this specific population during
AMI. We are currently expanding the size of the study
population to increase the power of our analysis. Our
findings were based on patients taking either glyburide or
glipizide. We may not find the same results in patients
treated with glimepiride or first-generation sulfonylureas
(low affinity for the KATP channel in the heart muscle).
Large-scale evaluations will be necessary to confirm these
preliminary findings and clarify these issues.
In summary, this is the first clinical study to suggest that
attenuation of electrocardiographic ST-segment elevation
during moderate-sized AMI occurs in diabetic patients
treated with sulfonylurea drugs. Because such attenuation of
ST-segment elevation may delay the diagnosis of AMI in
this subgroup of patients, we believe that the criteria for
thrombolysis or the use of another hypoglycemic agent
should be reconsidered in this high-risk population, provid-
ing further research confirms our observation.
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